Sign in to continue:

Saturday, August 1st, 2026

Kontoor Brands, Inc. 8-K SEC Filing June 12, 2026 – Company Details, Stock Info & Compliance Data





KONTOOR BRANDS, INC. Files Form 8-K: Key Details for Investors

KONTOOR BRANDS, INC. Files Form 8-K: Key Details for Investors

Overview

On June 15, 2026, Kontoor Brands, Inc. (NYSE: KTB), a leading manufacturer in the men’s and boys’ furnishings and work clothing sector, filed a Form 8-K with the United States Securities and Exchange Commission (SEC). This filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting events as of June 12, 2026.

Key Points from the Report

  • Form Type: 8-K (Current Report)
  • Date of Report: June 12, 2026
  • Trading Symbol: KTB
  • Exchange: New York Stock Exchange (NYSE)
  • Company Address: 400 N. Elm Street, Greensboro, NC 27401
  • Employer Identification Number (EIN): 83-2680248
  • Commission File Number: 001-38854
  • Emerging Growth Company: No (Kontoor Brands does not qualify as an emerging growth company)
  • Written Communications, Soliciting Material, Pre-commencement Tender Offer Communications: None (all indicated as false in the filing)

Important Developments for Shareholders

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Significance: This item is often a trigger for price-sensitive information as it typically relates to changes in the company’s leadership or executive compensation—factors that can influence investor sentiment and the company’s strategic direction.

No Material Transactions or Relationships Disclosed

The report specifies that there are no arrangements, understandings, or transactions with the newly reported officer, nor any family relationships with other directors or officers. Additionally, there are no transactions in which the company is a party and the new officer has a material interest that would require disclosure under Item 404(a) of Regulation S-K.

This indicates that, at this time, there are no new executive appointments or departures, nor any related-party transactions or compensation changes that would be considered price sensitive or likely to impact the share price.

Item 9.01 – Financial Statements and Exhibits

The only exhibit listed is the “Cover Page Interactive Data File,” embedded as an Inline XBRL document. No new financial statements, earnings releases, or major exhibits have been included with this filing.

Other Relevant Details

  • Company Status: The company is not an emerging growth company and has not elected any transition provisions for new or revised financial accounting standards.
  • Securities: The only security registered is “Common Stock, no par value” under the trading symbol KTB on the NYSE.
  • Contact Information: (336) 332-3400

Potential Impact on Share Price

Based on this 8-K filing, there are no new developments or disclosures that are likely to be price sensitive or significantly impact Kontoor Brands, Inc.’s share value. The filing is routine in nature, with no announcements regarding executive changes, material agreements, financial restatements, or other significant events.

Investors should continue to monitor future filings for any substantive announcements, but this particular 8-K does not contain material news expected to move the stock.


Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. Investors should review all official filings and consult their financial advisor before making investment decisions. The author and publisher assume no responsibility for any actions taken based on the information contained herein.




View Kontoor Brands, Inc. Historical chart here



Unusual Machines Expands Orlando Manufacturing Facility to Boost Domestic Drone Battery Production

Unusual Machines Expands Manufacturing Footprint in Orlando ...

Soleno Therapeutics Executive Compensation, Corporate Governance, and Pay Practices 2025

Soleno Therapeutics 2025 Annual Report - Key Investor Highli...